Alexa Fluor® 568 Anti-USP9x antibody [EPR13809(B)] - N-terminal,Abcam,AB312497
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human, Mouse
Application
ICC/IF, Target Binding Affinity, Antibody Labelling, IHC-P, Flow Cyt (Intra)
Conjugate
Alexa Fluor® 568
Platform ID
BAB923336110
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins (PubMed : 18254724, PubMed : 19135894, PubMed : 22371489, PubMed : 25944111, PubMed : 29626158, PubMed : 30914461, PubMed : 37454738). May therefore play an important regulatory role at the level of protein turnover by preventing degradation of proteins through the removal of conjugated ubiquitin (PubMed : 18254724, PubMed : 19135894, PubMed : 22371489, PubMed : 25944111, PubMed : 29626158, PubMed : 30914461, PubMed : 37454738). Specifically hydrolyzes 'Lys-11'-, followed by 'Lys-63'-, 'Lys-48'- and 'Lys-6'-linked polyubiquitins chains (PubMed : 30914461). Essential component of TGF-beta/BMP signaling cascade (PubMed : 19135894). Specifically deubiquitinates monoubiquitinated SMAD4, opposing the activity of E3 ubiquitin-protein ligase TRIM33 (PubMed : 19135894). Deubiquitinates alkylation repair enzyme ALKBH3 (PubMed : 25944111). OTUD4 recruits USP7 and USP9X to stabilize ALKBH3, thereby promoting the repair of alkylated DNA lesions (PubMed : 25944111). Deubiquitinates RNA demethylase enzyme ALKBH5, promoting its stability (PubMed : 37454738). Deubiquitinates mTORC2 complex component RICTOR at 'Lys-294' by removing 'Lys-63'-linked polyubiquitin chains, stabilizing RICTOR and enhancing its binding to MTOR, thus promoting mTORC2 complex assembly (PubMed : 33378666). Regulates chromosome alignment and segregation in mitosis by regulating the localization of BIRC5/survivin to mitotic centromeres (PubMed : 16322459). Involved in axonal growth and neuronal cell migration (PubMed : 24607389). Regulates cellular clock function by enhancing the protein stability and transcriptional activity of the core circadian protein BMAL1 via its deubiquitinating activity (PubMed : 29626158). Acts as a regulator of peroxisome import by mediating deubiquitination of PEX5 : specifically deubiquitinates PEX5 monoubiquitinated at 'Cys-11' following its retrotranslocation into the cytosol, resetting PEX5 for a subsequent import cycle (PubMed : 22371489). Deubiquitinates PEG10 (By similarity). Inhibits the activation of the Hippo signaling pathway via deubiquitination of AMOTL2 at 'Lys-347' and 'Lys-408' which prohibits its interaction with and activation of LATS2. Loss of LATS2 activation and subsequent loss of YAP1 phosphorylation results in an increase in YAP1-driven transcription of target genes (PubMed : 26598551, PubMed : 34404733). See full target information USP9X
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.